Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Breast Neoplasms × ixazomib × Clear all

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 9 Lymphoma 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Leukemia, Myeloid, Acute 2 Sarcoma, Ewing 1 Sarcoma, Alveolar Soft Part 1 Sarcoma 1 Recurrence 1 Neurofibrosarcoma 1 Neoplasms, Plasma Cell 1 Neoplasms 1 Neoplasm Metastasis 1 Liposarcoma 1 Leukemia, Plasma Cell 1 Leukemia, Biphenotypic, Acute 1 Immunoglobulin Light-chain Amyloidosis 1 Hematologic Neoplasms 1 Breast Neoplasms 1 Advanced Non-hematologic Malignancies 1 Advanced Cancers 1

Interventions

Paclitaxel 72 Trastuzumab 70 Fulvestrant 48 Cyclophosphamide 45 Lapatinib 39 Capecitabine 39 pembrolizumab 37 Docetaxel 35 palbociclib 31 Carboplatin 28 Letrozole 25 olaparib 21 Gemcitabine 21 Doxorubicin 21 Everolimus 18 Taxes 17 pertuzumab 16 abemaciclib 16 Magnetic Resonance Spectroscopy 16 Bevacizumab 16 Ado-Trastuzumab Emtansine 16 exemestane 15 Vinorelbine 15 Radiotherapy 15 Cisplatin 15 130-nm albumin-bound paclitaxel 15 ribociclib 14 Albumin-Bound Paclitaxel 14 Nivolumab 13 Filgrastim 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02384746 2019-04-29

Millennium

Dartmouth-Hitchcock Medical Center

Phase 1 Terminated

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡